GRFS Stock Analysis: Buy, Sell, or Hold?
GRFS - Grifois, S.A.
$7.93
-0.06 (-0.75%)
âŧ
5d:
+0.0%
30d:
+12.96%
90d:
+4.89%
WAIT
LOW Confidence
Analysis Updated: Aug 12, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Get Alerted When GRFS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: GRFS is fairly priced but lacks strong directional signals. At -2.1% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: GRFS is fairly priced but lacks strong directional signals. At -2.1% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$15.08
Based on 12.6% avg growth
INTRINSIC VALUE TODAY
$9.36
15.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 5.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GRFS is currently trading at $7.93, which is considered slightly high relative to its 30-day fair value range of $7.30 to $8.00. The stock's valuation (Forward PE: 5.6) is in line with its historical norms (5.9). Remarkably, the market is currently pricing in an annual earnings decline of 2.1% over the next few years. This pessimistic expectation contrasts with the company's recent 32.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GRFS is in a downtrend. The price is currently testing key support at $7.71. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GRFS scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.87 (+37.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GRFS is in a downtrend. The price is currently testing key support at $7.71. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GRFS scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.87 (+37.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$7.30 -
$8.00
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
42.9%
All Signals
- BEARISH: Weak technical setup (39/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 37.0% below Wall St target ($10.87)
- WARNING: Composite score 42/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$7.30 -
$8.00
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$7.71
Resistance Level
$8.37
Current Trend
Downtrend
Technical data as of
Aug 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.56
Wall Street Target
$10.87
(+37.0%)
Revenue Growth (YoY)
-0.9%
Earnings Growth (YoY)
32.9%
Profit Margin
6.1%
Valuation Discount vs History
-2.1% cheaper
PE vs Historical
5.6 vs 5.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.1%
(market-implied from PE analysis)
1-Year Target
$7.76
(-2%)
2-Year Target
$7.60
(-4%)
3-Year Target
$7.44
(-6%)
3-Yr Target (if PE normalizes)
(PE: 6â6)
$7.89
(-1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 21.1%)
$51.24
(+546%)
Base:
(SPY PE: 5.6, Growth: 21.1%)
$14.09
(+78%)
Bear:
(PE: 4.7, Growth: 21.1%)
$11.98
(+51%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (11x PE), but valuation improves significantly next year (6x PE) as earnings recover.
Trailing PE: 10.51 | Current EPS (TTM): $0.76
Bull Case
$16.49
(+108%)
Analyst growth 87.6%, PE expands to 11.6
Base Case
$14.99
(+89%)
Market implied 87.6%, PE stable at 10.5
Bear Case
$5.43
(-32%)
Severe decline -20.0%, PE contracts to 8.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.6 to 5.9
Stabilization Target:
$8.41
(+6.1%)
PE Expansion Potential:
+6.1%
Share & Embed Analysis
Last updated: August 13, 2026 1:23 AM ET
Data refreshes hourly during market hours. Next update: 2:23 AM
Data refreshes hourly during market hours. Next update: 2:23 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GRFS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1297 | 46 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 55 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$274 | 60 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$235 | 56 HOLD |
|
MRK
Merck & Company Inc |
BUY
26 analysts |
$137 | 47 HOLD |
